Objective To study the effect of tirofiban combined with simvastatin on quality of life and TIMI blood flow grading in young and middle-aged patients with acute myocardial infarction after PCI. Methods One hundred and thirty young patients with acute myocardial infarction who underwent coronary artery intervention（PCI）in our hospital from January 2016 to January 2018 were selected as the study subjects. They were randomly divided into observation group and control group

65 cases in each group. The control group was treated with routine medication

simvastatin plus PCI

while the observation group was treated with tirofiban. After treatment

the clinical efficacy

serological indicators

blood flow grading

quality of life and incidence of adverse reactions of thrombolytic therapy for myocardial infarction（TIMI） in the two groups were statistically analyzed and compared. Results The total effective rate was 90.77%（59/65） in the observation group and 76.92%（50/65） in the control group. There was statistical significance between the two groups（p<0.05）. After treatment

the levels of platelet aggregates（MPA）

creatine kinase isoenzyme（CK-MB） and troponin I（c TnI） in the observation group were lower than those in the control group

with statistical significance（p<0.05）. The proportion of patients with TIMI grade 3 in the observation group was higher than that in the control group

and the proportion of patients with grade 0 was lower than that in the control group. There was a statistical difference between the two groups（p<0.05）. The scores of quality of life including psychological function

physiological function

physical activity and social function in the observation group were higher than those in the control group

and there was significant difference between the two groups（p<0.05）. The incidence of adverse reactions was 13.85%（9/65） in the observation group and 7.69%（5/65） in the control group.There was no statistical difference between the two groups（p>0.05）. Conclusions Tirofiban combined with simvastatin is effective in the treatment of young and middle-aged patients with acute myocardial infarction after PCI. It can improve the serological indicators

TIMI blood flow grading

improve the quality of life of patients

and has good treatment safety

which is worthy of clinical recommendation.